Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? (Bone marrow transplantation, 2002)

(untitled) - Hale, G; Slavin, S; Goldman, J; Mackinnon, S; Giralt, S; Waldmann, H